Portal Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
Portal Therapeutics is a clinical stage biotechnology company, and the lead program in GondolaBio’s portfolio. Portal is developing a novel potential best-in-class therapy for erythropoietic protoporphyria, a severe genetic disease of the blood which results in extreme sensitivity to sunlight and liver damage. Portal recently initiated its Phase 2A trial upon generating a robust preclinical and Phase 1 dataset.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}